Development and characterization of a first-in-class small molecule inhibitor of PELP1

被引：0
|
作者：
Altwegg, Kristin A. [1 ]
Viswanadhapalli, Suryavathi [1 ]
Mann, Monica [1 ]
Pratap, Uday P. [1 ]
Li, Mengxing [1 ]
Liu, Junhao [1 ]
Luo, Yiliao [1 ]
Sareddy, Gangadhara R. [1 ]
Vankayalapati, Hariprasad [2 ]
Vadlamudi, Ratna K. [1 ]
机构：
[1] UT Hlth San Antonio, San Antonio, TX USA
[2] Huntsman Canc Inst, Salt Lake City, UT USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P3-10-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-10-01
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Identification and Characterization of the First Small Molecule Inhibitor of MDMX
    Reed, Damon
    Shen, Ying
    Shelat, Anang A.
    Arnold, Leggy A.
    Ferreira, Antonio M.
    Zhu, Fangyi
    Mills, Nicholas
    Smithson, David C.
    Regni, Catherine A.
    Bashford, Donald
    Cicero, Samantha A.
    Schulman, Brenda A.
    Jochemsen, Aart G.
    Guy, R. Kiplin
    Dyer, Michael A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (14) : 10786 - 10796
  • [42] Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor α
    Vadlamudi, RK
    Wang, RA
    Mazumdar, A
    Kim, Y
    Shin, J
    Sahin, A
    Kumar, R
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (41) : 38272 - 38279
  • [43] Development of a first-in-class small molecule inhibitor (EC359) targeting oncogenic LIF/LIFR signaling for the treatment of triple negative breast cancer
    Viswanadhapalli, S.
    Luo, Y.
    Sareddy, G. R.
    Santhamma, B.
    Zhou, M.
    Li, M.
    Pratap, U. P.
    Altwegg, K. A.
    Li, X.
    Srinivasan, U.
    Ma, S.
    Chang, A.
    Riveros, A. C.
    Zhang, K. Y.
    Dileep, K. V.
    Pan, X.
    Murali, R.
    Bajda, M.
    Raj, G.
    Brenner, A.
    Manthati, V.
    Rao, M.
    Tekmal, R. R.
    Nair, H. B.
    Nickisch, K. J.
    Vadlamudi, R. K.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Evaluation of a novel PELP1 inhibitor for treatment of triple negative breast cancer.
    Altwegg, Kristin A.
    Viswanadhapalli, Suryavathi
    Liu, Junhao
    Liu, Zexuan
    Pratap, Uday P.
    Vankayalapati, Hariprasad
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2021, 81 (13)
  • [45] FDA approves first-in-class AKT inhibitor
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (01) : 9 - 9
  • [46] FDA approves first-in-class SYK inhibitor
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (06) : 385 - 385
  • [47] FDA approves first-in-class AKT inhibitor
    Asher Mullard
    Nature Reviews Drug Discovery, 2024, 23 : 9 - 9
  • [48] PELP1 Overexpression in the Mouse Mammary Gland Results in the Development of Hyperplasia and Carcinoma
    Cortez, Valerie
    Samayoa, Cathy
    Zamora, Andrea
    Martinez, Lizatte
    Tekmal, Rajeshwar R.
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2014, 74 (24) : 7395 - 7405
  • [49] FDA approves first-in-class SYK inhibitor
    Asher Mullard
    Nature Reviews Drug Discovery, 2018, 17 : 385 - 385
  • [50] Romosozumab: A first-in-class scierostin inhibitor for osteoprosis
    Prather, Caitlin
    Adams, Erin
    Zentgraf, Whitney
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (23) : 1949 - 1956
12345